D-473

D-473 is an investigational small-molecule **triple monoamine reuptake inhibitor** based on a novel pyran scaffold that potently blocks the human serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT), with a serotonin-preferring profile (IC50 ≈ 9 nM for SERT, 40 nM for NET, 70 nM for DAT in cloned human transporters in HEK-293 cells).[1][3][6] In preclinical studies, orally administered D-473 showed good brain penetration, robust elevation of extracellular dopamine, serotonin, and norepinephrine in rat dorsal lateral striatum and medial prefrontal cortex by microdialysis, and significant antidepressant-like efficacy in the rat forced swim test without locomotor activation at optimal doses.[1][3][6] The compound was designed and characterized in the academic setting of Wayne State University as part of a pyran-based series of triple reuptake inhibitors for major depressive disorder and related CNS indications, and exhibits relatively selective transporter inhibition with limited off-target binding at a broad panel of CNS receptors.[1][3][4][5]